Acalabrutinib waa jiilka labaad ee tyrosine kinase (BTK) inhibitor, daawo cusub oo hagaajin karta badbaadada lymphocytic leukemia (CLL) iyo mantle cell lymphoma (MCL).
Cilmi-baadhayaashu waxay aaminsan yihiin in BTK inhibitors oo ay weheliyaan dawooyinka ka hortagga CD20 ee la beddelay (sida Obinutuzumab) ay hagaajin karaan xawaaraha iyo qoto dheer ee daaweynta Acalabrutinib iyagoo ka jawaabaya unugyada kansarka oo dheeraad ah.
Qeybta 1 b / II ee tijaabada caafimaadka, cilmi baarayaashu waxay qiimeeyeen saameynta daaweynta isku dhafan ee Acalabrutinib iyo Obinutuzumab ee Xarunta Kansarka ee Jaamacada Ohio-Isbitaalka James Cancer-Richard Research Center (OSUCCC-James), oo isugu yeeraya 45 dib u celin / diidmo ama bukaanka CLL ee aan weligood helin daaweyn.
Guud ahaan, daaweynta isku dhafka ah ee 'Acalabrutinib' iyo 'Obinutuzumab' ayaa si wanaagsan loo dulqaatay, heerka jawaab celintuna wuu soo fiicnaaday waqti ka dib.
Bukaannada aan helin wax daaweyn ah, heerka jawaabta guud waxay ahayd 95%. Muddada dabagalka dhexdhexaadku wuxuu ahaa 17.8 bilood. Qiyaasta guud ee badbaadada (OS) ee bukaannada qaba soo noqoshada / diidmada CLL waxay ahayd 92%, oo ay kujirto muddada dabagalka dhexdhexaadka ee 21 bilood.
OSUCCC-James. Khabiir ku xeel dheer iyo qoraaga koowaad Jennifer Woyach ayaa sheegtay in kastoo horumarka laga sameeyay daaweynta CLL sanadihii la soo dhaafay, haddana baahida loo qabo xulashooyinka daaweynta ee dheeraadka ah ay weli tahay mid deg deg ah.
Waxtarka guud ee tijaabada Acalabrutinib waxay xooga saaraysaa in daraasaddan kiliiniga ah ay saameyn ku yeelan karto maaraynta CLL.
